These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

953 related items for PubMed ID: 21108736

  • 1. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT, de Oliveira CP, Corrêa-Giannella ML, Soares IC, Kubrusly MS, Bellodi-Privato M, de Mello ES, de Lima VM, Carrilho FJ, Alves VA.
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [Abstract] [Full Text] [Related]

  • 2. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH.
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [Abstract] [Full Text] [Related]

  • 3. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.
    Sorrentino P, D'Angelo S, Ferbo U, Micheli P, Bracigliano A, Vecchione R.
    J Hepatol; 2009 Feb; 50(2):351-7. PubMed ID: 19070395
    [Abstract] [Full Text] [Related]

  • 4. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
    Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL.
    Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
    [Abstract] [Full Text] [Related]

  • 5. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease.
    Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY.
    J Gastroenterol Hepatol; 2009 Feb; 24(2):233-7. PubMed ID: 18713296
    [Abstract] [Full Text] [Related]

  • 6. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P.
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [Abstract] [Full Text] [Related]

  • 7. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.
    Cuadrado A, Orive A, García-Suárez C, Domínguez A, Fernández-Escalante JC, Crespo J, Pons-Romero F.
    Obes Surg; 2005 Mar; 15(3):442-6. PubMed ID: 15826485
    [Abstract] [Full Text] [Related]

  • 8. [Imaging of NASH].
    Tanimoto A, Tomita K.
    Nihon Rinsho; 2006 Jun; 64(6):1127-32. PubMed ID: 16768120
    [Abstract] [Full Text] [Related]

  • 9. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younossi ZM.
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [Abstract] [Full Text] [Related]

  • 10. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
    Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A.
    Int J Cancer; 2011 May 15; 128(10):2436-43. PubMed ID: 21128245
    [Abstract] [Full Text] [Related]

  • 11. [Clinical and histological features of non-alcoholic fatty liver disease].
    Shi JP, Xun YH, Hu CB, Zhang L, Liu H, Lou GQ, Fan JG.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov 15; 17(11):812-6. PubMed ID: 19958638
    [Abstract] [Full Text] [Related]

  • 12. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J, Petraki K, Kavantzas N, Rapti I, Kountouras D, Hadziyannis S.
    J Viral Hepat; 2005 Nov 15; 12(6):635-41. PubMed ID: 16255765
    [Abstract] [Full Text] [Related]

  • 13. Genomic aspects of NAFLD pathogenesis.
    Naik A, Košir R, Rozman D.
    Genomics; 2013 Aug 15; 102(2):84-95. PubMed ID: 23545492
    [Abstract] [Full Text] [Related]

  • 14. Proliferating cell nuclear antigen (PCNA) activity in hepatocellular carcinoma, benign peri-neoplastic and normal liver.
    Mun KS, Cheah PL, Baharudin NB, Looi LM.
    Malays J Pathol; 2006 Dec 15; 28(2):73-7. PubMed ID: 18376794
    [Abstract] [Full Text] [Related]

  • 15. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
    Serfaty L, Lemoine M.
    Diabetes Metab; 2008 Dec 15; 34(6 Pt 2):634-7. PubMed ID: 19195623
    [Abstract] [Full Text] [Related]

  • 16. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease.
    Chandok N, Minuk G, Wengiel M, Uhanova J.
    J Gastrointestin Liver Dis; 2012 Mar 15; 21(1):53-8. PubMed ID: 22457860
    [Abstract] [Full Text] [Related]

  • 17. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease.
    Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, Andrioti E, Theodossiades G, Archimandritis AJ.
    J Hepatol; 2009 Nov 15; 51(5):931-8. PubMed ID: 19726097
    [Abstract] [Full Text] [Related]

  • 18. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S, Yukawa T, Uetake S, Yamauchi M.
    Alcohol Clin Exp Res; 2007 Jan 15; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [Abstract] [Full Text] [Related]

  • 19. Natural history of nonalcoholic steatohepatitis.
    Liou I, Kowdley KV.
    J Clin Gastroenterol; 2006 Mar 15; 40 Suppl 1():S11-6. PubMed ID: 16540761
    [Abstract] [Full Text] [Related]

  • 20. Non-alcoholic steatohepatitis in children.
    Nanda K.
    Pediatr Transplant; 2004 Dec 15; 8(6):613-8. PubMed ID: 15598336
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.